Ultimovacs ASA: Annual Report 2022
March 24, 2023 03:00 ET
|
Ultimovacs ASA
Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs...
Ultimovacs to Present at Cowen Healthcare Conference
February 27, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, February 27, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces today that Carlos de Sousa, Chief...
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
February 16, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, February 16, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its fourth quarter 2022 results today. ...
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
February 09, 2023 02:00 ET
|
Ultimovacs ASA
Oslo, 9 February 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth...
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
January 23, 2023 02:00 ET
|
Ultimovacs ASA
Full recruitment of 118 patients with mesothelioma in Scandinavia, Spain and AustraliaThe study provides randomized data on impact of UV1 in combination with checkpoint inhibitors ipilimumab and...
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
December 20, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, 20 December 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that cemiplimab (Libtayo) will be...
Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer
December 14, 2022 02:00 ET
|
Ultimovacs ASA
First clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technologyFirst clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technology12 patients with prostate...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 29, 2022 11:00 ET
|
Ultimovacs ASA
Oslo, 29 November 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of...
Ultimovacs ASA: New share capital registered
November 21, 2022 01:00 ET
|
Ultimovacs ASA
Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Share capital increase related to exercise of options
November 16, 2022 05:56 ET
|
Ultimovacs ASA
Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the exercise of options, by NOK 13,070 through the...